Welcome to our dedicated page for AN2 Therapeutics news (Ticker: ANTX), a resource for investors and traders seeking the latest updates and insights on AN2 Therapeutics stock.
AN2 Therapeutics, Inc. (Nasdaq: ANTX) is a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform. The ANTX news feed highlights company announcements on its infectious disease and oncology pipeline, giving investors and observers direct access to official updates.
News about AN2 often centers on clinical development milestones for its lead programs in chronic Chagas disease, acute melioidosis, and nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium abscessus. Examples include initiation and progress of Phase 1 trials for AN2-502998 in Chagas disease, investigator-initiated trials of epetraborole in M. abscessus lung disease, and observational studies informing planned Phase 2 trials in melioidosis.
Readers can also follow strategic collaborations and global health initiatives, such as AN2’s partnership with the Drugs for Neglected Diseases initiative (DNDi) on AN2-502998 and its collaboration with GSK to advance boron-based LeuRS inhibitors targeting tuberculosis, supported by funding from the Gates Foundation. These items provide context on how AN2 integrates external expertise and non-dilutive funding into its development plans.
In addition, the ANTX news stream features quarterly financial results and business updates, where the company discusses its cash position, research and development spending, and progress across its boron chemistry pipeline, including emerging oncology programs focused on ENPP1 and PI3Kα. Conference participation, scientific presentations, and poster announcements, such as data on epetraborole’s activity against M. abscessus, also appear in the news flow.
By reviewing ANTX news, users can track how AN2 Therapeutics advances its boron-based therapeutics, monitors high-need infectious diseases, and develops oncology candidates over time.
AN2 Therapeutics (Nasdaq: ANTX) has announced a strategic collaboration with Drugs for Neglected Diseases initiative (DNDi) to advance the clinical development of AN2-502998, an oral drug candidate for chronic Chagas disease treatment. The partnership leverages DNDi's extensive clinical trial network and expertise in Latin America and Spain.
The collaboration aims to accelerate the development of AN2-502998, with Phase 1 first-in-human studies currently starting and Phase 2 studies planned for 2026. Chagas disease, affecting 6-7 million people globally including 300,000 in the U.S., is caused by the Trypanosoma cruzi parasite and can lead to serious heart and gastrointestinal complications in approximately 30% of chronic cases.
AN2 Therapeutics (Nasdaq: ANTX) has completed a significant 200-patient observational study in acute melioidosis, funded by the National Institutes of Health. The study revealed a striking 40% mortality rate by Day 90 among confirmed melioidosis cases, with an additional 25% of screened patients dying before definitive diagnosis.
The study was conducted across three sites in melioidosis-endemic regions, evaluating patients receiving the current standard of care (IV meropenem or ceftazidime). The research was completed in just 11 months and tracked patients for over 90 days, providing critical data for the company's upcoming Phase 2 proof-of-concept trial of epetraborole.
The company plans to submit an IND and initiate its Phase 2 trial later this year. If approved for acute melioidosis treatment, AN2 Therapeutics would seek a priority review voucher and could generate revenue from government stockpiling and treatment use in endemic countries, including the U.S., as B. pseudomallei is classified as a high-priority biothreat agent.
AN2 Therapeutics (NASDAQ: ANTX) announced a poster presentation at the 2025 Colorado Mycobacteria Conference showcasing preclinical data of epetraborole against M. abscessus. The presentation, scheduled for May 29, 2025, will highlight the drug's potential as an oral treatment for M. abscessus lung disease, which affects approximately 50,000 patients in the U.S., Japan, and Europe, with an estimated all-cause mortality rate of 45%. The poster, titled "Epetraborole, a Potential Oral Agent for Mycobacterium abscessus Lung Disease," will be presented by Dr. MRK Alley and will be simultaneously available on AN2 Therapeutics' website.
Pipeline developments:
- Initiated Phase 1 study for AN2-502998 in Chagas disease, with potential $1 billion peak sales
- Planning Phase 2 study of epetraborole for melioidosis
- Advancing epetraborole for M. abscessus NTM lung disease
- Developing oncology programs targeting ENPP1 and PI3Kα
Financial results show reduced losses with net loss of $10.6 million vs $16.6 million in Q1 2024. R&D expenses decreased to $7.7 million from $14.7 million, while G&A expenses slightly increased to $3.8 million from $3.6 million.
AN2 Therapeutics, a biopharmaceutical company specializing in boron chemistry platform and small molecule therapeutics, has announced its participation in the upcoming 2025 Citizens JMP Life Sciences Conference in New York.
Eric Easom, who serves as Co-Founder, Chairman, President and CEO, will engage in a fireside chat on May 7, 2025, at 9:00 am ET. The management team will also be available for one-on-one meetings during the conference, which runs from May 7-8, 2025.
Investors and interested parties can access the webcast through AN2 Therapeutics' website investor section, with a replay available for at least 30 days following the event.
AN2 Therapeutics (ANTX) reported its Q4 and full year 2024 financial results, highlighting key pipeline developments. The company expects Phase 3 topline data for epetraborole in treatment-refractory MAC lung disease in Q2 2025. A Phase 1 study for AN2-502998 in Chagas disease is planned for mid-2025, while melioidosis trial data is expected in Q2 2025.
Financial highlights include cash position of $88.6 million as of December 31, 2024, expected to fund operations through 2027. Full-year 2024 R&D expenses were $40.5 million, down from $54.9 million in 2023. The company reported a net loss of $51.3 million for 2024, improved from $64.7 million in 2023.
The company amended its statistical analysis plan, selecting QOL-B respiratory domain as the primary efficacy endpoint for the Phase 3 epetraborole trial. Additionally, ANTX is advancing its boron chemistry platform with first oncology candidates expected in 2H25.
AN2 Therapeutics (Nasdaq: ANTX), a biopharmaceutical company specializing in boron chemistry platform-derived small molecule therapeutics, has announced its participation in the upcoming Leerink Partners Global Healthcare Conference.
Eric Easom, who serves as Co-Founder, Chairman, President and CEO, will deliver a corporate overview on March 12, 2025, at 2:20 pm ET. The management team will also be available for one-on-one meetings during the conference.
Investors and interested parties can access the presentation webcast through the Investors section of AN2 Therapeutics' website. The replay will remain available for a minimum of 30 days after the presentation.
AN2 Therapeutics (NASDAQ: ANTX) has announced a strategic update for its Phase 3 EBO-301 trial in treatment-refractory MAC lung disease. The company has submitted an amended statistical analysis plan to the FDA, selecting the Quality of Life – Bronchiectasis (QOL-B) respiratory domain patient reported outcome as the primary efficacy endpoint.
In the Phase 2 study, epetraborole showed nominal statistical superiority versus placebo, with a difference in least squares mean change from baseline of 6.90 (p=0.0365). The company plans to unblind Phase 3 data in Q2 2025, which includes 97 completed subjects. If Phase 3 data confirms Phase 2 findings, AN2 will discuss potential registrational pathways with the FDA for this highly refractory population.
This approach aligns with FDA's 2023 Guidance for Industry on NTM drug development and follows the precedent of Insmed's confirmatory Arikayce study in treatment-naïve MAC patients.
AN2 Therapeutics (Nasdaq: ANTX), a biopharmaceutical company specializing in boron chemistry platform-derived small molecule therapeutics, has announced its participation in two major investor conferences in March 2025.
At the TD Cowen 45th Annual Health Care Conference, Co-Founder, Chairman, President and CEO Eric Easom will deliver a corporate overview on March 3, 2025, at 2:30 pm ET. The management team will also be available for one-on-one meetings.
The company will also attend the Leerink Partners Global Healthcare Conference on March 12, 2025, where management will conduct one-on-one meetings. The TD Cowen conference presentation will be webcasted and accessible through AN2 Therapeutics' website, with a replay available for at least 30 days post-presentation.